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Aim: To determine the effect of HIV syndrome on lipid profile in a cohort of Nigerians. 
 
Objective: To determine the concentrations of total cholesterol (Tchol), triglyceride (TGL), high density lipoprotein (HDL), and 
low density lipoprotein (LDL) in HIV positive drug naive patients as against HIV negative people. 
 
Methods: This study examined the lipid profiles of 50 HIV positive individuals (test group), and 50 HIV negative individuals 
(control group) at the Human Virology Laboratory of Nigerian Institute of Medical Research (NIMR), Lagos, Nigeria. Informed 
consent was obtained and the Institutional Review Board (IRB) of NIMR approved the study. A questionnaire based assessment 
was provided for the individuals to complete, before 5 ml of blood was taken by venopuncture. Blood collected in plain tubes 
was centrifuged at 3500 rpm for 10 minutes and the serum obtained, used for the various lipid profile tests mentioned above. 
Statistical analysis on data from the questionnaire was done using Epi info 2000 (CDC). 
 
Results: The median lipid profile values for the control group were 168, 85, 99 and 58 mg/dl for Tchol, TGL, HDL and LDL 
respectively.   Conversely, median lipid profile values for the HIV positive patients were 145, 98, 53, and 67 mg/dl for Tchol, 
TGL, HDL and LDL respectively. P values greater than 0.05 were taken to indicate an insignificant difference between the lipid 
profiles of the two groups. 
 
Conclusion: Based on results obtained, there were significant differences in the Tchol and HDL values between the two groups, 
indicating a possible effect of HIV on lipid profile for drug naive patients. 
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INTRODUCTION 
Lipids, a diverse group of compounds which serve as 
storage compounds, structural components, cofactors 
and pigments, are found almost universally as stored 
forms of energy in living organisms as derivatives of 
fatty acids. Phospholipids and sterols are components 
of cell membranes [1]. Some serve as hormones, or as 
intracellular messengers generated in response to an 
extracellular signal. Others function as enzyme 
cofactors in electron-transfer reactions in chloroplasts 
and mitochondria [1]. Fairly current knowledge 
regarding the etiology of altered lipid metabolism in 
HIV-positive patients does not afford a clear picture 
as to whether HIV disease itself or antiretroviral 
therapy   (ART)   is   largely   to   blame;   there   are 
proponents on each side of the debate [2]. 
HIV-infected  individuals,  both  those  on  ART  and 
those who are untreated, appear to have higher rates 
of coronary heart disease (CHD) than HIV-uninfected 
individuals and higher rates of various risk factors for 
CHD, including dyslipidemia. HIV itself causes lipid 
perturbations, particularly in persons with more 
advanced immunosuppression; HIV-infected 
individuals who are not on antiretroviral (ARV) 
medications often have elevations in triglyceride (TG) 
levels   and   decreases   in   high-density   lipoprotein 
(HDL) as  well  as  in  low-density lipoprotein (LDL) 
and  total  cholesterol (TC).  Lipid  abnormalities also 
may be caused by or compounded by ARVs [3]. 
 
Studies on lipid profile have focused on antiretroviral 
drug-induced lipid changes of HIV infected people. 
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Findings have been controversial, with some studies 
stating an increased lipid profile [4,5], and others 
reduced levels of some lipids. Few studies have 
documented drug naive lipid profile changes. 
 
Cases of AIDS have been reported in every nation of 
the world, yet the disease affects some countries more 
than others. More than 95% of all HIV-infected people 
live in the developing world [6,7]. The use of effective 
ART  has  resulted  in  tremendous improvements in 
morbidity and mortality of HIV-infected individuals 
[7]. However there have been various studies linking 
HIV antiretroviral therapy with excess lipid 
depositions  and  abnormalities  [8].  The  widespread 
use of effective ART regimens has coincided with 
increasing reports of metabolic abnormalities such as 
impaired glucose metabolism and insulin resistance, 
lactic acidosis, osteopenia, and dyslipidemia [8]. 
 
Nutrition is of vital importance because it improves 
resistance and slows the progression of AIDS. 
Nutritional needs of HIV patients include increased 
intake of protein, vitamins, minerals and enough 
kilocalories to prevent weight loss and to meet 
increased metabolic demands. 
 
Although lipid metabolism in HIV patients on ART 
and drug naive HIV patients (much less)  has  been 
widely studied across the globe, none to our 
knowledge has been done in our locality. Hence this 
study was undertaken to investigate the lipid profile 
of   HIV   patients,   to   assess   if   HIV   infection   is 
implicated in aggravating the normal lipid profile of 





This was a case controlled study carried out between 
HIV positive drug naive and HIV negative persons. 
Recruitment period was from May to July, 2010. One 
hundred individuals were recruited, whose ages 
ranged between 20 to 55 years, with a mean of 34.2 
years. Fifty HIV positive and 50 HIV negative, 
apparently healthy individuals were  recruited from 
the Human Virology and the Clinical Diagnostic 
Laboratories of the Nigerian Institute of Medical 
Research    (NIMR)    Yaba,    Lagos,    Nigeria.    The 
individuals were randomly selected using a simple 
random   sampling   technique.   The   HIV   negative 
persons were mostly Staff and Interns of the two 
laboratories. Inclusion criteria for the study were HIV 
seropositivity and antiretroviral naive status with 
clinical/laboratory stage of  CD4  above 350  cells/µl 




ETHICAL CLEARANCE; INFORMED CONSENT 
Ethical clearance was obtained from the Institutional 
Review Board of NIMR. Informed consent of patients 
was obtained before including them in the study. The 
study did not interfere with clinical management and 
the confidentiality of patients was maintained by de- 
identifying the specimens. 
 
QUESTIONNAIRE DISTRIBUTION 
Copies of a questionnaire were distributed to the 100 
people, where data on physical parameters, (age, sex, 
etc) eating habits before and after HIV diagnosis were 
collected. The Control group (50) did not answer the 
‘After  diagnosis’  section  of  the  questionnaire. The 
questionnaires  were  collected  after  filling,  entered 




COLLECTION OF BLOOD SAMPLES 
Five ml of blood was collected by clear venopuncture 
into plain vacutainers. The samples were centrifuged 




Cholesterol  was  determined  by  enzymatic 
colorimetric method of Randox (United Kingdom) [9]. 
The cholesterol is determined after enzymatic 
hydrolysis and oxidation. The indicator quinoneimine 
was formed from hydrogen peroxide and 4- 
aminoantipyrine in the presence of phenol and 
peroxidase to give a pinkish coloration. 
 
TRIGLYCERIDE ANALYSIS 
Triglyceride was determined using Randox kits; a 
lipoprotein lipase from microorganisms for the rapid 
and complete hydrolysis of  triglycerides to  glycerol 
followed  by   oxidation  to   dihydroxyacetone 






4-aminophenazone and 4-chlorophenol under the 
catalytic action of peroxidase to form a red dye 




LOW DENSITY LIPOPROTEIN ANALYSIS 
LDL was determined using a direct method (Randox). 
This   method   takes   advantage   of   the   selective 
micellary   solubilisation   of   LDL   by   a   nonionic 
detergent and the interaction of a  sugar compound 
and lipoproteins (VLDL and chylomicrons). 
 
HIGH DENSITY LIPOPROTEIN ANALYSIS 
HDL was determined by an enzymatic colorimetric 
method (Randox). This method uses polyethylene 
glycol-modified enzymes and dextran sulfate. When 
cholesterol esterase and cholesterol oxidase enzymes 
are modified by  PEG, they  show  selective catalytic 
activities toward lipoprotein fractions, with the 
reactivity increasing in the order: LDL< VLDL ≈ 
chylomicrons < HDL. 
 
RESULTS 
Mean weight was 67.3 kg for the control group (HIV-) 
and 62.6 kg for the test group (HIV+), giving an 
insignificant difference (p>0.05) between them. Their 
mean heights were 1.61 m and 1.63 m for the control 
and  test  groups respectively. Sex  distribution male: 
female ratio was 15:35, and 26:24 for the test and 
control groups respectively. Mean age was 34.2 years 
for both the control group and HIV positive 
individuals. The marital status showed 64% and 54% 
were married; 36% and 42% were single; while 0% 
and 4% were separated for the test and control groups 
respectively (Table 1). 
 
From analysis of the questionnaires, eating habits 
before    diagnosis    and    after,    showed    a    slight 
improvement  towards  healthy  eating  in   the   test 
group. Figure 1 presents the lipid profile of the two 
groups of people with normal ranges (low and high) 
beside each parameter. Median total cholesterol, 
triglyceride, HDL and LDL was 168, 85, 99  and 58 
mg/dl for the control group respectively; and 145, 98, 
53 and 67 mg/dl for the test group respectively (Table 
2). 
 
DISCUSSION AND CONCLUSION 
In   this   study,   lipid   profile   was   comparatively 
analyzed for  50  HIV positive and 50  HIV  negative 
individuals in Lagos, South-western Nigeria. Both 
groups were closely matched in their mean ages (both 
34.2 years). Heights and weights were also in general, 
fairly average. Body Mass Index (BMI) was 23.5 and 
25.7   for   the   HIV   positive  and   negative  groups 
respectively. This ironically shows an apparently 
healthy HIV positive group and a slightly overweight 
HIV negative group.  The observed differences in the 
values obtained after data analysis were statistically 
significant (p<0.05) for two of the parameters tested, 
Tchol and HDL, but insignificant for TGL and LDL. 
Significantly higher Tchol and HDL values were 
observed for the HIV negative group than the positive 
group. 
 
These findings may be a factor pointing towards an 
initiation  of   body   fat   redistribution  in   the   HIV 
infected people. Altered lipid metabolism is known to 
affect immune processes.         Caraciolo et al [10] 
characterized the lipid profile of asymptomatic 
untreated HIV positive individuals compared with a 
control group. They investigated the relationship 
between serum lipid levels and CD4 lymphocytes 
(CD4) and viral load (VL) of asymptomatic untreated 
HIV positive men who have sex with men (MSM), 
 
 
TABLE   1:   PHYSICAL   PARAMETERS   OF   THE   50   HIV   POSITIVE   (TEST)   AND   50    HIV   NEGATIVE   (CONTROL)   GROUPS 
 
PARAMETER HIV positive HIV negative P  value 
mean Weight (kg) 62.6 67.3 0.05 
mean Height (m) 1.63 1.62 0.53 
mean Age (years) 34.2 34.2 0.98 

















































TABLE  2:  LIPID  PROFILE  OF  THE  50  HIV  POSITIVE  PATIENTS  AND  50  NEGATIVE  CONTROL  GROUPS 
(*- statistically significant) 
 
 
PARAMETER HIV Positive HIV Negative P  value 
median TChol (mg/dl) 145 168 0.001* 
median TGL (mg/dl) 98 85 0.105 
median HDL (mg/dl) 53 99 0.000* 
 









comparing it with a control group, in Spain. They 
stated  that  the  slightly  lowered  lipid  variations 
observed, excluding antiretroviral therapy, hepatic 
and nutritional effects might be due to HIV action. 





Elevations in serum TChol and TGL levels, along with dyslipidemia that typically occur in patients with HIV 
infection, may predispose patients to complications such as premature atherosclerosis, particularly coronary 
heart  disease,  and  pancreatitis [11].      It  remains  to  be  seen  if  lipid  metabolism  is  altered  at  initiation of 
antiretrovirals (PI- or NNRTI-based) as reported in a study [8]. Adewole et al, [12] stated that abnormalities in 
serum lipid are common among treatment naive HIV patients. The results obtained here are in partial support to 
that of Adewole et al [12].   In conclusion, in this study the presence of HIV infection affected some of the lipid 
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Figure 1: The median lipid profile of the HIV positive (test) and the HIV negative (control) groups 
 
These findings however may be inconclusive due to the relatively small sample size utilized in this study. A 
broader study, involving the immunologic parameters (CD4, CD8), and viral load is recommended to further 
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